CF-focused Sionna goes public in $135M IPO, while Aardvark plots $103M listing
Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity biotech Aardvark Therapeutics unveiled plans for a nine-figure IPO of its own.
Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity biotech Aardvark Therapeutics unveiled plans for a nine-figure IPO of its own.
